Four risk prediction models have been shown to accurately select the highest risk smokers for lung cancer screening. READ MORE
Health care resource use and approaches to clinical management of advanced non-small cell lung cancer vary significantly in eight different countries.
Specific ALK variants may be linked to the development of ALK resistance mutations and poor clinical outcomes in patients with non-small cell lung cancer.
Targeted next-generation sequencing may accurately estimate tumor mutation burden in NSCLC, which may further shed light on the likelihood of benefit from immune checkpoint inhibitors in individual patients.
A recent study examined whether the Lung Immune Prognostic Index was associated with resistance to immunotherapy in patients with advanced non-small cell lung cancer.